Alterity Therapeutics LTD income statement

In fiscal 2018, Alterity Therapeutics LTD reported revenue of $155,962, up 56.1% on the year before and net income of −$6.4m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Alterity Therapeutics LTD: income statement, annual
Fiscal year	2016Jun 2016	2017Jun 2017	2018Jun 2018
Revenue	104	100	156
Research and development	6,986	4,300	5,193
General and administrative	792	514	700
Income before tax	−5,634	−5,690	−6,408
Income tax	0	0	0
Net income	−5,634	−5,690	−6,408
Diluted shares (average)	44m	44m	44m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alterity Therapeutics LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alterity Therapeutics LTD.